Abstract:This work developed a biohybrid bacterial system through genetic engineering and biomaterial hybridization in which CDH17 nanobodies are engineered onto the bacteria for tumor targeting and a photothermal material croconium (CR) dye is conjugated on bacteria for PTT induction. When combined with checkpoint blockade CD47 nanobody, the biohybrid bacteria successfully eradicated the tumors through STING activation, and considerably extended survival of the mice. Bacteria can be utilized for cancer therapy owing to their preferential colonization at tumor sites. However, unmodified non‐pathogenic bacteria carry potential risks due to their non‐specific targeting effects, and their anti‐tumor activity is limited when used as monotherapy. In this study, a biohybrid‐engineered bacterial system comprising non‐pathogenic MG1655 bacteria modified with CDH17 nanobodies on their surface and conjugated with photosensitizer croconium (CR) molecules is developed. The resultant biohybrid bacteria can efficiently home to CDH17‐positive tumors, including gastric, pancreatic, and colorectal cancers, and significantly suppress tumor growth upon irradiation. More importantly, biohybrid bacteria‐mediated photothermal therapy (PTT) induced abundant macrophage infiltration in a syngeneic murine colorectal model. Further, that the STING pathway is activated in tumor macrophages by the released bacterial nucleic acid after PTT is revealed, leading to the production of type I interferons. The addition of CD47 nanobody but not PD‐1 antibody to the PTT regimen can eradicate the tumors and extend survival. This results indicate that bacteria endowed with tumor‐specific selectivity and coupled with photothermal payloads can serve as an innovative strategy for low‐immunogenicity cancers. This strategy can potentially reprogram the tumor microenvironment by inducing macrophage infiltration and enhancing the efficacy of immunotherapy targeting macrophages.

In Situ Synthesis of an Immune-Checkpoint Blocker from Engineered Bacteria Elicits a Potent Antitumor Response

In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Bacteria engineered with intracellular and extracellular nanomaterials for hierarchical modulation of antitumor immune responses

Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity

Ultrasound-controllable engineered bacteria for cancer immunotherapy

Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms

Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity

Entirely Synthetic Bacterial Nanomimics for Highly-Effective Tumor Suppression and Immune Elicitation

T cell cascade regulation initiates systemic antitumor immunity through living drug factory of anti-PD-1/IL-12 engineered probiotics

Engineered Bacteria: Strategies and Applications in Cancer Immunotherapy

Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance

Development of a Bacteria-Nanosapper for the Active Delivery of ZIF-8 Particles Containing Therapeutic Genes for Cancer Immune Therapy

In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy

In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors

Sequential delivery of photosensitizers and checkpoint inhibitors by engineered bacteria for enhanced cancer photodynamic immunotherapy

Engineered Bacteriophage-Based in Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity.

Nanobody‐Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING‐Mediated Anti‐Tumor Immunity

A Shear-Thinning Biomaterial-Mediated Immune Checkpoint Blockade.